Terralpha harnesses ADVA TeraFlex™ for 600G transport throughout France
27.1.2022 11:00:00 EET | Business Wire | Press release
ADVA (FSE: ADV) today announced that Terralpha has deployed its FSP 3000 TeraFlex™ terminal to transport data at speeds up to 600Gbit/s between cities across France. The solution enables Terralpha – the new service provider arm of France’s SNCF railway group – to use its spare fiber capacity to offer low-latency, ultra-high-speed connectivity to customers. Now, enterprises, mobile network operators and government institutions can leverage flexible, highly reliable services for edge computing and 5G applications. What’s more, Terralpha’s network will enable homes and businesses in many underserved areas to access next-generation broadband and mobile connectivity. The new solution also features ADVA’s FSP 3000 OLS, flexgrid multi-degree ROADMs, its ALM fiber monitoring technology and its Ensemble Controller network management and control solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220126005706/en/
ADVA’s TeraFlex™ technology is helping Terralpha to drive 600G connectivity throughout France. (Photo: Business Wire)
“With around 20,000km of fiber deployed alongside our railway infrastructure, we knew we were in a unique position to offer super-fast connectivity right across France. What we needed was a transport solution with the capacity, flexibility and scale to match our ambitions and a partner we could trust. In ADVA, we have a European technology provider with a wealth of experience and an excellent track record for success,” said Gabriel Chenevoy, CEO of Terralpha. “The ADVA team has worked with us to deliver a solution that maximizes the value of our existing network and empowers us to provide our customers with a new level of bandwidth capacity and service quality. Our backbone infrastructure will be key to closing the digital divide by delivering high-speed services in a highly efficient and sustainable way to around 100 tier 3 cities within two years. The performance of ADVA’s equipment combined with our straight and diverse routes has enabled us to reduce actual latencies between major cities in France from 10% to 40%, supporting new latency-sensitive applications.”
The ADVA FSP 3000 TeraFlex™ terminal is specifically designed to inject enormous capacity into deployed networks without operators having to spend significant amounts on overhauling their infrastructure. With its software-defined fractional QAM modulation and adaptive baud rate capabilities, the low-power 1RU terminal is now ensuring optimal spectrum utilization in Terralpha’s transport system. The network is managed by ADVA’s Ensemble Controller, which supports programmatic SDN control, further improving efficiency by reducing troublesome and time-consuming manual processes. The infrastructure is also continuously assured by ADVA’s ALM fiber monitoring technology with precise fault localization from Ensemble Fiber Director. This enables Terralpha’s maintenance teams to quickly detect and pinpoint any degradation in the fiber plant and resolve issues before services are affected.
“We’re helping Terralpha to unlock the full value of its fiber assets. By harnessing our technology and the expertise of our engineers, Terralpha can take advantage of its vast network architecture to bring reliable, low-latency services at unprecedented speeds to homes, businesses and service provider customers in every corner of France,” commented Hartmut Müller-Leitloff, SVP of sales, EMEA at ADVA. “One of the keys to the success of this project has been our close collaboration with the Terralpha team to make sure the new solution meets their exact requirements. That’s helped us deliver a turnkey solution that works seamlessly with Terralpha’s existing network to provide optimal performance over every single link. With our scalable technology and continuing support, there’s no limit to what Terralpha can achieve.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
About Terralpha
Incorporated in 2021, Terralpha, a 100% subsidiary of SNCF Réseau, offers Ultra High Speed data transport services. Its DNA “Ultra High Speed for all territories” is supported by an ambition to deploy Ultra High Speed and high reliability points of presence throughout France. The choice of architecture and transmission equipment, of European origin, enables to create circuits between cities at speeds of 100Gb/s to 600Gb/s at very low latency.
Terralpha’s mission is to ensure the trusted routing of data traffic through fully owned active and passive infrastructure. Additionally, and in order to facilitate the development of regional data centers, Terralpha offers a range of hosting solutions called ”Digital Tiles” to host the equipment necessary for the storage and the processing of information locally. Each of these “Digital Tiles” has a dual fiber connection to the Terralpha network, and to the public networks to meet the strategic requirements of data centers. www.terralpha.fr
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220126005706/en/
Contact information
For ADVA press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For ADVA investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
For Terralpha press:
Hervé Legay
t +33 1 84 21 15 07
contact@terralpha.fr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN ® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 09:00:00 EEST | Press release
Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month 6 as the primary endpoint. Secondary endpoints include changes in monthly headache days, acute medication days and migraine frequency during two-week periods at the end of each injection cycle. “Achieving patient recruitment for both MINT-C and MINT-E six months ahead of plan is an important milestone for our XEOMIN® migraine preven
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 08:10:00 EEST | Press release
Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Malaysia 2026–2027 (VM2026–2027), this partnership merges Tourism Malaysia’s destination marketing with Alipay+’s global wallet ecosystem and AI capabilities. It aims to create a highly intelligent digital journey, connecti
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe atopic dermatitis, sustained through Week 52.1 The results will be presented at The Pediatric Dermatology Research Alliance (PeDRA) Annual Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014705800/en/ Up to 25% of children are affected by atopic dermatitis - the most common inflammatory skin disorder in this population - and around one-third of these children have moderate-to-severe disease.11,12 Atopic dermatitis creates a high burden for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school, and social confidence.2-8 Despite the high prevalence and significant burden, treatment options are
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 03:30:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re excited at the potential to fundamentally change how NT1 is managed across Japan and China,” said Giles Platford, president, International, Takeda. “We’ve heard from patients how ORZEYFUL has improved their daily functioning and quality of life, enormously meaningful outcomes for a condition known to impact many aspects of a person’s life, including work, education and social interactions.”1,2,3,4,5 NT1 is a chronic, rare neurological disease driven by orexin deficiency. People experience a range of symptoms including excessive daytime sleepiness, cataplexy (sudden loss of muscle tone), disr
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 03:10:00 EEST | Press release
Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to expand treatment options for patients with IBD.2,3 On October 18, Celltrion will host a symposium titled "Navigating the Treatment Journey with Subcutaneous Infliximab Across Clinical Scenarios," Chaired by Professor Peter M. Irving of King's College London, UK, a leading IBD expert. Celltrion will also host two MTE sessions at its booth. In the firs
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
